Despite decades of research and untold investments of time, energy, and money, treatments for sepsis other than antibiotics and supportive care have remained elusive. Over this time, our expanding understanding of the biology of sepsis has led to the development of targeted treatments, including immunomodulatory and anticoagulant approaches, yet so far all of these approaches have been ultimately unsuccessful.
With this historical backdrop, much recent translational research in sepsis has focused on the importance of vascular endothelial permeability, a pathophysiologic hallmark of the syndrome and the focus of the work of Alfi eri and colleagues in the previous issue of Critical Care [1] . Th e angiopoietin (Ang)-1/2 axis is a key regulator of endothelial permeability, operating via the Tie-2 receptor on vascular endothelial cells. Ang-1, the primary Tie-2 agonist, decreases capillary leak and inhibits leukocyte-endothelial interaction, among other eff ects [2] [3] [4] . In contrast, Ang-2, produced primarily in endothelial cells, functions as a context-dependent Tie-2 antagonist [5, 6] . Elegant experimental and translational studies have clearly demonstrated that Ang-2 plays a critical role in the organ injury of sepsis by mediating increased endothelial permeability [7, 8] . Likewise, clinical studies have identifi ed a strong association between lower Ang-1 and/or higher Ang-2 levels and poor clinical outcomes in sepsis, including acute lung injury, pulmonary leak index, multi-organ dysfunction, and mortality [6, [9] [10] [11] . Th us, manipulation of the Ang-1/2 axis has become an appealing therapeutic target.
One challenge of therapeutic intervention on the Ang-1/2 axis is that recombinant human Ang-1 has poor solubility and a short half-life [12] . Th us, alternative approaches to eff ective delivery of Ang-1 have been investigated in experimental models. Cartilage oligomeric matrix protein-angiopoietin-1 (COMP.Ang-1) is a soluble and stabilized variant that binds more avidly to Tie-2 than native Ang-1 [12] . COMP.Ang-1, adenovirusdelivered Ang-1, recombinant human Ang-1, cell-based therapies, and a synthetic Tie-2 agonist all reduce vascular leak and end-organ dysfunction in murine sepsis models [13] [14] [15] [16] [17] [18] [19] . Each of these approaches has some appeal; Alfi eri and colleagues chose to investigate the eff ects of a modifi ed Ang-1 molecule, MAT.Ang-1, formed by fusing the coiled-coil domain of human matrilin-1 to the fi brinogen-like domain of human Ang-1. MAT.Ang-1 has better solubility than recombinant Ang-1 and yet more similar biologic activity to native Ang-1 than COMP.Ang-1 [12] .
To study the eff ects of this modifi ed Ang-1 in experimental models of sepsis, Alfi eri and colleagues implanted window chambers into the dorsal skinfolds of mice, so as to visualize skeletal muscle blood fl ow with laser Doppler Abstract Angiopoietin-1 is a Tie-2 receptor agonist that stabilizes vascular endothelium, promoting endothelial maturation and preventing capillary leak. Angiopoietin-2 is largely a competitive partial antagonist that is markedly elevated in humans and animal models of sepsis and other infl ammatory states, directly disrupts the endothelial barrier, and has been correlated with end-organ dysfunction and death in sepsis. In the previous issue of Critical Care, Alfi eri and colleagues used intravital microscopy to study the microvasculature in a murine model of sepsis. Treatment with a modifi ed angiopoietin-1 molecule led to reversal of albumin vascular leak and improved blood fl ow to skeletal muscle, as well as a decrease in the levels of several infl ammatory cytokines. Importantly, the angiopoietin-1 variant was administered 20 hours after initial lipopolysaccharide challenge. This study adds to the evidence that the angiopoietin/Tie-2 axis represents a modifi able pathway through which targeted therapy may be able to directly reverse part of the pathology of sepsis. imaging. Lipopolysaccharide (LPS) was injected intraperitoneally at 0 and 19 hours, followed by intravenous MAT.Ang-1 at 20 hours. MAT.Ang-1 returned LPSinduced leak of albumin to control levels at 23 and 24 hours, without aff ecting vascular permeability in mice untreated with LPS. Microvascular perfusion at 24 hours partially improved in LPS-challenged mice treated with MAT.Ang-1, but did not return to normal. In addition to its eff ects on vascular permeability and perfusion, MAT. Ang-1 reduced tumor necrosis factor alpha, interferon gamma, triggering receptor expressed on myeloid cells-1, granulocyte colony-stimulating factor, and IL-10 in LPSunchallenged mice, a novel fi nding given that other studies have not treated well mice with Tie-2 agonists. LPS-induced elevation in IL-1β, IL-10, and IL-1 receptor antagonist was decreased by MAT.Ang-1, consistent with two other Tie-2 agonists' eff ects on infl ammatory cytokines [14, 20] . What can we learn from this new study, and how has it advanced the fi eld? First, MAT.Ang-1 was given after the administration of LPS, rather than prophylactically. While the therapeutic interval was short, this treatment model highlights the possibility that a Tie-2 agonist could be a feasible therapy for the microvascular dysfunction of sepsis. Second, although MAT.Ang-1 was described previously, this study represents its fi rst therapeutic trial in this setting. Th ird, the in vivo imaging of skeletal muscle provides an interesting window into micro vascular function and a novel demonstration of the potential therapeutic eff ects of manipulation of the Ang1/2 axis.
At the same time, many questions about the eff ects of this modifi ed Ang-1 compound remain unanswered. In the current paper, only eff ects on skeletal muscle vasculature and expression of cytokines and angiogenic factors were assessed. What might lung intravital microscopy, which has become a valuable scientifi c tool in models of acute lung injury, reveal about the eff ects of MAT.Ang-1 on the pulmonary vascular bed and leukocyte traffi cking in the lung? More broadly, what are the eff ects of MAT.Ang-1 on organ injury and mortality in experimental models of sepsis? How does MAT.Ang-1 aff ect the immune response, including bacterial counts, in live bacterial models? Perhaps most importantly, how do diff erent approaches to manipulating the Ang-1/2 axis compare in the same experimental sepsis models?
While many questions remain, this work by Alfi eri and colleagues adds to the growing weight of literature highlighting the potential value of targeting the vascular endothelium in sepsis and will certainly pique the interest of the many researchers who are continuing the decadeslong quest for the holy grail of a targeted sepsis therapy.
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